SenzaGen moves into their new laboratories at Medicon Village

In June, SenzaGen moves into its new lab facilities at Medicon Village in Lund. As SenzaGen is expanding, establishing new partnerships and customers and is hiring more staff, the company has a demand to set up in new premises and gather the business.

In June, SenzaGen moves into its new lab facilities at Medicon Village in Lund. As SenzaGen is expanding, establishing new partnerships and customers and is hiring more staff, the company has a demand to set up in new premises and gather the business. The lab is completely new and is equipped with the latest technology to implement the tests.

– The new lab is a natural step in SenzaGen’ss commercialization of what we have developed here at the department of Immunotechnology. Research and development is continuing at LTH, says Malin Lindstedt , founder and CSO of SenzaGen .

The opening of the lab was celebrated with new and old colleagues as well as investors, owners and business partners of SenzaGen.

SenzaGen wins innovation prize SKAPA and is appointed as provincial finalist.

SenzaGen has won yet another award and was recently appointed the provincial finalist in Skåne and will thereby have the opportunity to win the national innovation award SKAPA, the country's largest and most prestigious innovation prize. The SKAPA Prize is awarded to innovators in order to support the commercialization of their products.

SenzaGen wins innovation prize SKAPA and is appointed as provincial finalist.

SenzaGen has won yet another award and was recently appointed the provincial finalist in Skåne and will thereby have the opportunity to win the national innovation award SKAPA, the country's largest and most prestigious innovation prize. The SKAPA Prize is awarded to innovators in order to support the commercialization of their products.

The prize is awarded by the Foundation SKAPA in cooperation with ALMI. It is the regional ALMI companies in cooperation with local inventors' associations affiliated to the Swedish Inventors Association which has chosen the county finalists for the award.

The appointment means that SenzaGen have the opportunity to be appointed Swedish champion of innovation. As the county finalist, SenzaGen receives a prize worth SEK 25 000 with the option to gain an additional SEK 550 000 (maximum spread over three laureates) if they succeed as winners of the national prize.

"SenzaGen has been able to package advanced research in a transparent, commercial way and have in a short time shown that they will be able to both significantly minimize the number of animal tests being performed and deliver a better accuracy in the tests and hence a better value to their customers. It is going to be very exciting to follow the company in the future!" says Johan Olsen, ALMI Innovation.

For more information please contact:

Anki Malmborg Hager, CEO, SenzaGen AB
amh@senzagen.com
+46 768 284822

Ian Kimber joins the board of SenzaGen AB

SenzaGen AB, a diagnostic spin-off company from Lund University, is proud to announce that Prof. Ian Kimber will join the Board of Directors.

Prof Ian Kimber is currently Professor of Toxicology and Associate Dean for Business Development in the Faculty of Life Sciences at the University of Manchester. He has broad research interests at the interface between toxicology and immunology, with a particular focus on allergy and inflammation. Professor Kimber holds, and has held, a variety of positions on national and international expert and scientific advisory committees. Currently these include the following: Member UK Medicines and Healthcare products Regulatory Agency (MHRA) Committee for Safety of Devices, Programme Advisor Food Standards Agency Food Allergy and Intolerance Research Programme, and member MRC Translational Research Group. Professor Kimber was previously President of the British Toxicology Society (BTS) (2012-2014), and Chairman of the Board of the UK National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) (2008-2013).

“I am delighted to be joining the Board of SenzaGen at such an exciting period of growth. Since our initial studies that led to the development and ultimate validation of the Local Lymph Node Assay I have maintained a keen interest in chemical allergy and in the development of novel approaches for improved hazard identification and risk assessment. In this respect harnessing fully the opportunities afforded by developments in the biomedical sciences is critical, and the work of SenzaGen in exploiting a genomic approach to pathway analysis and risk assessment is at the cutting edge of new developments”, says Prof Kimber.

Ian Kimber has published over 600 research papers, review articles and book chapters, and serves currently on the editorial boards of toxicology, immunology, dermatology and pathology journals.

“We are very happy to have Prof Kimber on board in SenzaGen”, since he is one of the forerunners in sensitization testing, says Prof Carl Borrebaeck, “his knowledge and interest in the field of allergy and replacement of animal testing with new technologies is very important to us. We value his participation in developing the next generation tests.”

About SenzaGen

SenzaGen AB is an early-phase diagnostics company based on strong research and know-how of the immune system and its reaction to hazardous agents, such as irritants and allergens. The company’s products are genetic tests for sensitizing agents, which have been designed based on how indicator cells react when exposed to a variety of chemicals.

SenzaGen AB was created to meet the international demand to replace existing animal testing for regulatory purposes and to provide novel tools for early decision-making in product development. SenzaGen AB services will offer the most accurate, animal-free in vitro testing option for manufacturers of cosmetics, chemicals, food, and pharmaceuticals.

SenzaGen AB is a spin-off company founded by researchers at Lund University to bring academic results to good use for society. The company is situated in facilities at Medicon Village, Lund, Sweden.

www.senzagen.com

For more information please contact:

Anki Malmborg Hager, CEO, SenzaGen AB

amh@senzagen.com

+46 768 284822

Ian Kimber joins the board of SenzaGen AB

SenzaGen AB, a diagnostic spin-off company from Lund University, is proud to announce that Prof. Ian Kimber will join the Board of Directors.
SenzaGen AB is a diagnostic company working to replace animal testing for sensitization predictions.

SenzaGen AB, a diagnostic spin-off company from Lund University, is proud to announce that Prof. Ian Kimber will join the Board of Directors.

SenzaGen AB is a diagnostic company working to replace animal testing for sensitization predictions.

Prof Ian Kimber is currently Professor of Toxicology and Associate Dean for Business Development in the Faculty of Life Sciences at the University of Manchester. He has broad research interests at the interface between toxicology and immunology, with a particular focus on allergy and inflammation. Professor Kimber holds, and has held, a variety of positions on national and international expert and scientific advisory committees. Currently these include the following: Member UK Medicines and Healthcare products Regulatory Agency (MHRA) Committee for Safety of Devices, Programme Advisor Food Standards Agency Food Allergy and Intolerance Research Programme, and member MRC Translational Research Group. Professor Kimber was previously President of the British Toxicology Society (BTS) (2012-2014), and Chairman of the Board of the UK National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) (2008-2013).

“I am delighted to be joining the Board of SenzaGen at such an exciting period of growth. Since our initial studies that led to the development and ultimate validation of the Local Lymph Node Assay I have maintained a keen interest in chemical allergy and in the development of novel approaches for improved hazard identification and risk assessment. In this respect harnessing fully the opportunities afforded by developments in the biomedical sciences is critical, and the work of SenzaGen in exploiting a genomic approach to pathway analysis and risk assessment is at the cutting edge of new developments”, says Prof Kimber.

Ian Kimber has published over 600 research papers, review articles and book chapters, and serves currently on the editorial boards of toxicology, immunology, dermatology and pathology journals.

“We are very happy to have Prof Kimber on board in SenzaGen”, since he is one of the forerunners in sensitization testing, says Prof Carl Borrebaeck, “his knowledge and interest in the field of allergy and replacement of animal testing with new technologies is very important to us. We value his participation in developing the next generation tests.”

For more information please contact:

Anki Malmborg Hager, CEO, SenzaGen AB
amh@senzagen.com
+46 768 284822

SenzaGen one of the five most praised companies in Swedish business media

SenzaGen one of the five most praised companies at Ny Teknik & Affärsvärldens big Inovation Event for the 33 most promising young innovativ companies in Sweden.

SenzaGen one of the five most praised companies at Ny Teknik & Affärsvärldens big Inovation Event for the 33 most promising young innovativ companies in Sweden.

The final ceremony for the 33-list was held in Stockholm were the hottest new technology companies in Sweden were presented. The list is presented without ranking but five companies were elected for special attention and SenzaGen was awarded a prize from ALMI, a strategic partner and SenzaGen given investment money for further development of the company.

Anki Malmborg Hager, CEO of SenzaGen features in film about the company from the event.
https://vimeo.com/124938396  (in Swedish)

For more information please contact:
Anki Malmborg Hager, CEO, SenzaGen AB
amh@senzagen.com
+46 768 284822

SenzaGen AB expands product portfolio to include respiratory sensitization

SenzaGen AB, a diagnostic spin-off company from Lund University, reports the launch of a new product for respiratory sensitization testing.

SenzaGen AB, a diagnostic spin-off company from Lund University, reports the launch of a new product for respiratory sensitization testing.

SenzaGen AB is a diagnostic company working to replace animal testing for sensitization predictions.

-“Sensitization through the lung is a growing issue and methods to predict if a chemical has a sensitization effect are limited”, says Anki Malmborg Hager, CEO in SenzaGen. Based on extensive research about the responses of the immune system in allergic reactions, SenzaGen has now launched a test that predicts the respiratory sensitization ability of chemicals based on the GARD methodology.

An international scientific article about the underlying research has been published in PLOS ONE, under the title “Prediction of Chemical Respiratory Sensitizers Using GARD, a Novel In vitro Assay Based on a Genomic Biomarker Signature”. http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0118808

SenzaGen´s first product, a skin sensitization test of chemicals, is already on the market.

About SenzaGen

SenzaGen AB is an early-phase diagnostics company based on strong research and know-how of the immune system and its reaction to hazardous agents, such as irritants and allergens. The company’s products are genetic tests for sensitizing agents, which have been designed based on how indicator cells react when exposed to a variety of chemicals.

SenzaGen AB was created to meet the international demand to replace existing animal testing for regulatory purposes and to provide novel tools for early decision-making in product development. SenzaGen AB services will offer the most accurate, animal-free in vitro testing option for manufacturers of cosmetics, chemicals, food, and pharmaceuticals.

SenzaGen AB is a spin-off company founded by researchers at Lund University to bring academic results to good use for society. The company is situated in facilities at Medicon Village, Lund, Sweden.

www.senzagen.com

For more information please contact:

Anki Malmborg Hager, CEO, SenzaGen AB

amh@senzagen.com

+46 768 284822

SenzaGen AB expands product portfolio to include respiratory sensitization

SenzaGen AB, a diagnostic spin-off company from Lund University, reports the launch of a new product for respiratory sensitization testing.

SenzaGen AB is a diagnostic company working to replace animal testing for sensitization predictions.

“Sensitization through the lung is a growing issue and methods to predict if a chemical has a sensitization effect are limited”, says Anki Malmborg Hager, CEO in SenzaGen. Based on extensive research about the responses of the immune system in allergic reactions, SenzaGen has now launched a test that predicts the respiratory sensitization ability of chemicals based on the GARD methodology.

An international scientific article about the underlying research has been published in PLOS ONE, under the title “Prediction of Chemical Respiratory Sensitizers Using GARD, a Novel In vitro Assay Based on a Genomic Biomarker Signature”. http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0118808

SenzaGen´s first product, a skin sensitization test of chemicals, is already on the market.

For more information please contact:

Anki Malmborg Hager, CEO, SenzaGen AB
amh@senzagen.com
+46 768 284822

Ny Teknik & Affärsvärlden list SenzaGen AB as one of the 33 most promising young innovative companies in Sweden

On Tuesday, SenzaGen AB achieved a position on the so called 33-list in Sweden after winning Lund local elevator pitch for NyTeknik and Affärsvärlden 33-list.

On Tuesday, SenzaGen AB achieved a position on the so called 33-list in Sweden after winning Lund local elevator pitch for NyTeknik and Affärsvärlden 33-list.

After several interviews by the organisers, a challenging questioning by an initiated jury and a smashing elevator pitch, Senzagen acquired a position on the renowned 33-list.

The 33-list is based on propositions of companies from all over Sweden and the winners are chosen collectively by the editorial staff at the two journals Ny Teknik and Affärsvärlden. The jury is looking for companies with a unique product or service based on a clear innovation with great international potential – an innovation with the ability to change the rules in the business. To qualify for a position on the list, the company must be based in Sweden and be less than 7 years. Read more on (in Swedish) http://www.33-listan.se 

Link to the article in Ny Teknik 2015, March 2: http://www.nyteknik.se/33listan/article3889772.ece (Swedish)

For more information
Anki Malmborg Hager, 0768-284 822, amh@senzagen.com
SenzaGen AB, www.senzagen.com

SenzaGen AB completes successful collaboration with Beiersdorf

SenzaGen AB, a diagnostic spin-off company from Lund University, reports the successful completion of a collaboration with Beiersdorf.

SenzaGen AB, a diagnostic company working to replace animal testing, has been collaborating with Beiersdorf to evaluate its skin sensitization test for chemicals.

SenzaGen AB, a diagnostic spin-off company from Lund University, reports the successful completion of a collaboration with Beiersdorf.

SenzaGen AB, a diagnostic company working to replace animal testing, has been collaborating with Beiersdorf to evaluate its skin sensitization test for chemicals.

SenzaGen AB is based on research at the Department of Immunotechnology at Lund University, providing animal-free, in vitro sensitization tests for the cosmetic, chemical, pharmaceutical and food industries.

Beiersdorf has been working in the development and recognition of alternative methods for more than 20 years and is one of the main players in the cosmetic industry in Europe. An industry that is highly interested in recommendations in this field – especially after the ban in March 2013 on animal testing in the cosmetic industry.

“It has been very valuable for SenzaGen to be able to challenge its skin sensitization test in an industrial setting.” says Prof. Carl Borrebaeck, chairman of the board of SenzaGen.

In the collaboration, blind testing of two industrial test sets of chemicals were performed using the SenzaGen proprietary GARD assay, resulting in an accuracy of 89%.

www.senzagen.com

For more information please contact:

Carl Borrebaeck, Chairman of the Board, SenzaGen AB
carl.borrebaeck@immun.lth.se

+46 708 218330

SenzaGen AB completes successful collaboration with Beiersdorf

SenzaGen AB completes successful collaboration with Beiersdorf

2014-11-19, Lund, Sweden

SenzaGen AB, a diagnostic spin-off company from Lund University, reports the successful completion of a collaboration with Beiersdorf.

SenzaGen AB, a diagnostic company working to replace animal testing, has been collaborating with Beiersdorf to evaluate its skin sensitization test for chemicals.

SenzaGen AB is based on research at the Department of Immunotechnology at Lund University, providing animal-free, in vitro sensitization tests for the cosmetic, chemical, pharmaceutical and food industries.

Beiersdorf has been working in the development and recognition of alternative methods for more than 20 years and is one of the main players in the cosmetic industry in Europe. An industry that is highly interested in recommendations in this field – especially after the ban in March 2013 on animal testing in the cosmetic industry.

“It has been very valuable for SenzaGen to be able to challenge its skin sensitization test in an industrial setting.” says Prof. Carl Borrebaeck, chairman of the board of SenzaGen.

In the collaboration, blind testing of two industrial test sets of chemicals were performed using the SenzaGen proprietary GARD assay, resulting in an accuracy of 89%.

About SenzaGen

SenzaGen AB is an early-phase diagnostics company based on strong research and know-how of the immune system and its reaction to hazardous agents, such as irritants and allergens. The company’s products are genetic tests for sensitizing agents, which have been designed based on how indicator cells react when exposed to a variety of chemicals.

SenzaGen AB was created to meet the international demand to replace existing animal testing for regulatory purposes and to provide novel tools for early decision-making in product development. SenzaGen AB services will offer the most accurate, animal-free in vitro testing option for manufacturers of cosmetics, chemicals, food, and pharmaceuticals.

SenzaGen AB is a spin-off company founded by researchers at Lund University to bring academic results to good use for society. The company is situated in facilities at Medicon Village, Lund, Sweden.

www.senzagen.com

For more information please contact:

Carl Borrebaeck, Chairman of the Board, SenzaGen AB

carl.borrebaeck@immun.lth.se

+46 708 218330